Staff Reports
The Supreme Court’s move to extend a short pause on a lower‑court ruling over the abortion pill is proof that Washington can’t stop meddling in every hard question facing the states. Justice Samuel Alito quietly pushed the break button this week, keeping the Food and Drug Administration’s rules for mifepristone in place for a few more days while the high court sorts emergency appeals. That little delay matters — for providers, pharmacies, and millions of patients — and it should matter to anyone who cares about law, procedure, and commonsense limits on federal power.
What Justice Alito actually did — and why it matters
Justice Alito extended an administrative stay that preserves the FDA’s post‑2023 rules allowing mifepristone to be prescribed by telehealth and shipped through the mail. In plain English: for now, telehealth pills and mail delivery remain legal while the Supreme Court reviews emergency requests from the drugmakers. The applicants — Danco Laboratories and GenBioPro — asked the Court to halt a Fifth Circuit order that would force patients to make in‑person visits again. The Court asked the FDA and Louisiana to respond, which means a bigger fight is on the way.
Why the Fifth Circuit pushed back — and who’s right
The Fifth Circuit said Louisiana is likely to win on the merits and criticized how the FDA removed the in‑person dispensing rule in its REMS change. That panel argued the agency’s decision undercuts state abortion limits and that the FDA short‑circuited proper procedure. If you believe in states’ rights and sensible administrative law, that point resonates. The FDA changed rules in January 2023 that allowed mail and retail pharmacy dispensing of mifepristone; the Fifth Circuit sees that as an agency acting like a policymaker, not a regulator following the rulebook.
Conservative priorities: law, safety, and predictable governance
Conservatives should be clear‑eyed about two things. First, this is not about “who wins” in the short term; it’s about whether federal agencies can rewrite rules that erase state policy without real legal grounding. Second, the telehealth‑by‑mail model for abortion drugs raises serious questions about accountability, medical oversight, and state sovereignty. If the FDA had a compelling case, it should welcome a full, prompt judicial review rather than lean on temporary stays that keep policies frozen by status quo bias. Kicking the can down the road benefits no one and rewards regulatory overreach.
What to watch next — and why readers should care
The Supreme Court has a few clear options: let the short stay expire and allow the Fifth Circuit order to take effect, extend the stay while calling for more briefing, or set a schedule for fuller review. Any outcome will be headline news, but the deeper issue is whether courts will check an agency that changed national policy affecting millions. For conservatives who favor limited government and respect for state law, the right result is obvious: let the legal process run its course and don’t let an unelected bureaucratic change steamroll state authority. The next few days will show whether the justices care about that principle — and whether Washington continues to treat serious legal questions like a never‑ending regulatory free‑for‑all.
